Relief Therapeutics Holding AG (0QKQ.L)

CHF 4.05

(-8.58%)

Market Cap (In CHF)

52.95 Million

Revenue (In CHF)

6.03 Million

Net Income (In CHF)

-98.18 Million

Avg. Volume

219.00

Currency
CHF
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.4-8.24
PE
-
EPS
-
Beta Value
-14.74
ISIN
CH1251125998
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Mr. Paolo Galfetti
Employee Count
-
Website
https://www.relieftherapeutics.com
Ipo Date
2021-01-18
Details
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.